Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
- PMID: 16865597
- DOI: 10.1245/ASO.2006.08.011
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
Abstract
With recent advances in pancreatic imaging and surgical techniques, a distinct subset of pancreatic tumors is emerging that blurs the distinction between resectable and locally advanced disease: tumors of "borderline resectability." In our practice, patients with borderline-resectable pancreatic cancer include those whose tumors exhibit encasement of a short segment of the hepatic artery, without evidence of tumor extension to the celiac axis, that is amenable to resection and reconstruction; tumor abutment of the superior mesenteric artery involving <180 degrees of the circumference of the artery; or short-segment occlusion of the superior mesenteric vein, portal vein, or their confluence with a suitable option available for vascular reconstruction because the veins are normal above and below the area of tumor involvement. With currently available surgical techniques, patients with borderline-resectable pancreatic head cancer are at high risk for a margin-positive resection. Therefore, our approach to these patients is to use preoperative systemic therapy and local-regional chemoradiation to maximize the potential for an R0 resection and to avoid R2 resections. In our experience, patients with favorable responses to preoperative therapy (radiographical evidence of tumor regression and improvement in serum tumor marker levels) are the subset of patients who have the best chance for an R0 resection and a favorable long-term outcome.
Comment in
-
Borderline resectable pancreatic cancer: a new classification for an old challenge.Ann Surg Oncol. 2006 Aug;13(8):1019-20. doi: 10.1245/ASO.2006.02.902. Epub 2006 Jul 19. Ann Surg Oncol. 2006. PMID: 16865593 No abstract available.
Similar articles
-
Defining venous involvement in borderline resectable pancreatic cancer.Ann Surg Oncol. 2010 Nov;17(11):2832-8. doi: 10.1245/s10434-010-1284-9. Epub 2010 Aug 20. Ann Surg Oncol. 2010. PMID: 20725860
-
[The technique of radical pancreaticoduodenectomy for malignant tumor in pancreatic head with pressed superior mesenteric blood vessels or portal vein].Zhonghua Wai Ke Za Zhi. 2008 Mar 1;46(5):366-9. Zhonghua Wai Ke Za Zhi. 2008. PMID: 18785534 Chinese.
-
Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.Am J Clin Oncol. 2008 Dec;31(6):545-52. doi: 10.1097/COC.0b013e318172d5c5. Am J Clin Oncol. 2008. PMID: 19060585 Clinical Trial.
-
[Resectability of pancreatic cancer: New criteria].Radiologe. 2016 Apr;56(4):318-24. doi: 10.1007/s00117-016-0092-z. Radiologe. 2016. PMID: 26993121 Review. German.
-
Venous resection in pancreatic cancer surgery.Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64. doi: 10.1016/j.bpg.2005.11.003. Best Pract Res Clin Gastroenterol. 2006. PMID: 16549332 Review.
Cited by
-
Response evaluation following neoadjuvant treatment of pancreatic cancer patients.World J Gastrointest Surg. 2013 Feb 27;5(2):12-5. doi: 10.4240/wjgs.v5.i2.12. World J Gastrointest Surg. 2013. PMID: 23515366 Free PMC article.
-
Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.PLoS One. 2012;7(12):e50956. doi: 10.1371/journal.pone.0050956. Epub 2012 Dec 26. PLoS One. 2012. PMID: 23300530 Free PMC article.
-
Perioperative and long-term outcomes after pancreaticoduodenectomy in elderly patients 80 years of age and older.Langenbecks Arch Surg. 2013 Apr;398(4):531-8. doi: 10.1007/s00423-013-1072-7. Epub 2013 Mar 6. Langenbecks Arch Surg. 2013. PMID: 23462741
-
The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.Cancer Sci. 2021 Jul;112(7):2895-2904. doi: 10.1111/cas.14914. Epub 2021 May 19. Cancer Sci. 2021. PMID: 33931909 Free PMC article.
-
Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes.Ann Surg Oncol. 2023 Jun;30(6):3479-3488. doi: 10.1245/s10434-023-13120-3. Epub 2023 Feb 15. Ann Surg Oncol. 2023. PMID: 36792768
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical